These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30388368)

  • 41. Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib.
    Amaya GM; Durandis R; Bourgeois DS; Perkins JA; Abouda AA; Wines KJ; Mohamud M; Starks SA; Daniels RN; Jackson KD
    Chem Res Toxicol; 2018 Jul; 31(7):570-584. PubMed ID: 29847931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sophora flavescens (Ku-Shen) as a booster for antiretroviral therapy through cytochrome P450 3A4 inhibition.
    Lin ZX; Che CT; Lee SS; Chan RC; Ip PS; Yang JM
    Hong Kong Med J; 2015 Dec; 21 Suppl 7():S18-21. PubMed ID: 26908268
    [No Abstract]   [Full Text] [Related]  

  • 43. Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.
    Ishikawa Y; Akiyoshi T; Imaoka A; Ohtani H
    Biopharm Drug Dispos; 2017 Oct; 38(7):420-425. PubMed ID: 28425104
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects.
    Li Y; Ning J; Wang Y; Wang C; Sun C; Huo X; Yu Z; Feng L; Zhang B; Tian X; Ma X
    Toxicol Lett; 2018 Sep; 294():27-36. PubMed ID: 29753067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.
    Chen Q; Ngui JS; Doss GA; Wang RW; Cai X; DiNinno FP; Blizzard TA; Hammond ML; Stearns RA; Evans DC; Baillie TA; Tang W
    Chem Res Toxicol; 2002 Jul; 15(7):907-14. PubMed ID: 12119000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition.
    Lawhorn BG; Tran T; Hong VS; Morgan LA; Le BT; Harpel MR; Jolivette L; Diaz E; Schwartz B; Gross JW; Tomaszek T; Semus S; Concha N; Smallwood A; Holt DA; Kallander LS
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4838-4843. PubMed ID: 28985999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimization of 2,4-diamino-5-fluoropyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions and P-gp liability.
    Kunikawa S; Tanaka A; Mukoyoshi K; Nagashima S; Tominaga H; Chida N; Tasaki M; Shirai F
    Bioorg Med Chem; 2015 Jul; 23(13):3269-77. PubMed ID: 25982074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Iridoid Glycosides from Tabebuia avellanedae.
    Suo MR; Yan SY
    Chem Biodivers; 2016 Dec; 13(12):1611-1616. PubMed ID: 27454549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of Mechanism-Based Inhibition of CYP 3A4 by a Series of Fluoroquinolone Antibacterial Agents.
    Watanabe A; Takakusa H; Kimura T; Inoue S; Kusuhara H; Ando O
    Drug Metab Dispos; 2016 Oct; 44(10):1608-16. PubMed ID: 27469000
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimization of a novel series of N-phenylindoline-5-sulfonamide-based acyl CoA:monoacylglycerol acyltransferase-2 inhibitors: Mitigation of CYP3A4 time-dependent inhibition and phototoxic liabilities.
    Sato K; Takahagi H; Kubo O; Hidaka K; Yoshikawa T; Kamaura M; Nakakariya M; Amano N; Adachi R; Maki T; Take K; Takekawa S; Kitazaki T; Maekawa T
    Bioorg Med Chem; 2015 Aug; 23(15):4544-4560. PubMed ID: 26100443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
    Kharasch ED; Whittington D; Hoffer C; Krudys K; Craig K; Vicini P; Sheffels P; Lalovic B
    Clin Pharmacokinet; 2005; 44(7):731-51. PubMed ID: 15966756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
    Xu L; Chen Y; Pan Y; Skiles GL; Shou M
    Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative Evaluation of Cytochrome P450 3A4 Inhibition and Hepatotoxicity in HepaRG 3-D Spheroids.
    Shin DS; Seo H; Yang JY; Joo J; Im SH; Kim SS; Kim SK; Bae MA
    Int J Toxicol; 2018; 37(5):393-403. PubMed ID: 29923436
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sulfonamides as Selective Na
    Weiss MM; Dineen TA; Marx IE; Altmann S; Boezio A; Bregman H; Chu-Moyer M; DiMauro EF; Feric Bojic E; Foti RS; Gao H; Graceffa R; Gunaydin H; Guzman-Perez A; Huang H; Huang L; Jarosh M; Kornecook T; Kreiman CR; Ligutti J; La DS; Lin MJ; Liu D; Moyer BD; Nguyen HN; Peterson EA; Rose PE; Taborn K; Youngblood BD; Yu V; Fremeau RT
    J Med Chem; 2017 Jul; 60(14):5969-5989. PubMed ID: 28287723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.
    Filppula AM; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2013 Jan; 41(1):50-9. PubMed ID: 23028140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of cytochrome P450-mediated bioactivation of a compound containing the chemical scaffold, 4,5-dihydropyrazole-1-carboxylic acid-(4-chlorophenyl amide), to a chemically reactive p-chlorophenyl isocyanate intermediate in human liver microsomes.
    Chen H; Zientek M; Jalaie M; Zhang Y; Bigge C; Mutlib A
    Chem Res Toxicol; 2009 Sep; 22(9):1603-12. PubMed ID: 19697924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4.
    Nishikawa H; Inoue T; Masui T; Izumi T; Nakagawa S; Koyama T
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):591-6. PubMed ID: 18950380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acetaminophen analog N-acetyl-m-aminophenol, but not its reactive metabolite, N-acetyl-p-benzoquinone imine induces CYP3A activity via inhibition of protein degradation.
    Santoh M; Sanoh S; Ohtsuki Y; Ejiri Y; Kotake Y; Ohta S
    Biochem Biophys Res Commun; 2017 May; 486(3):639-644. PubMed ID: 28341123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering.
    Saeui CT; Liu L; Urias E; Morrissette-McAlmon J; Bhattacharya R; Yarema KJ
    Mol Pharm; 2018 Mar; 15(3):705-720. PubMed ID: 28853901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.